<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293643</url>
  </required_header>
  <id_info>
    <org_study_id>P08077</org_study_id>
    <secondary_id>BR 001-09</secondary_id>
    <nct_id>NCT01293643</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)</brief_title>
  <official_title>A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to compare the safety and efficacy of the use of a intravaginal ovule
      containing a combination of Ketoconazole and Clindamycin to the use of an intravaginal cream
      containing a combination Tetracycline and Amphotericin B for the treatment of bacterial
      vaginosis and/or mixed or isolated vaginal candidiasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants that obtain clinical cure</measure>
    <time_frame>Baseline up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants that obtain microbiological cure</measure>
    <time_frame>Baseline up to Day 10</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Vaginosis, Bacterial</condition>
  <condition>Candidiasis, Vulvovaginal</condition>
  <arm_group>
    <arm_group_label>clindamycin/ketoconazole combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tetracycline hydrochloride/amphotericin B combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg clindamycin /800 mg ketoconazole vaginal ovule</intervention_name>
    <description>1 vaginal ovule for 3 consecutive days</description>
    <arm_group_label>clindamycin/ketoconazole combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg tetracycline hydrochloride /50 mg amphotericin B cream</intervention_name>
    <description>1 applicator (4 g) full of cream intravaginally for 7 to 10 days</description>
    <arm_group_label>tetracycline hydrochloride/amphotericin B combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of vaginal candidiasis

          -  No Trichomonas vaginalis or any other protozoa

          -  No clinical evidences of infection by Neisseria gonorrhoeae, Chlamydia trachomatis, or
             viral infections

        Exclusion Criteria:

          -  Known sensitivity to the formula components

          -  Pregnant or nursing patients

          -  Any gynecological condition contraindicating the use of vaginal ovule or cream.

          -  Use of any other local or systemic bactericidal, anti-protozoa or antifungal agent
             within the 2 weeks prior to the study start or during it

          -  Presence of other sexually transmitted diseases (except from Candidal vaginitis).

          -  History of recurrent candidiasis (â‰¥4 episodes per year)

          -  Use of intra-uterine device, spermicides, or diaphragms

          -  Has metabolic or immune disorder

          -  Has abnormal uterine bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

